Aimmune Therapeutics, Inc. (NYSE:AIMT) was founded on June 24, 2011, headquartered in Brisbane, California, USA, with 21 full-time employees (6/30/2015). It is a clinical-stage biopharmaceutical company focusing on Research and development of new drugs and new therapies for food allergy.
Aimmune Therapeutics (AIMT):
Aimmune is a Delaware company established in June 2011-Allergen Research Corporation, which changed its current name to Aimmune Therapeutics, Inc. in May 2015.
According to statistics, more than 300,000 people in the United States and Europe have a history of food allergies. Among them, peanut allergy is the most common. In severe cases, it can be life-threatening. Aimmune’s new therapy is a customized oral desensitization immunity (CODIT) biological product that can accurately process allergens.
AR101 is the company’s main product candidate and has completed phase II clinical trials. Aimmune plans to start phase III clinical trials in early 2016 and plans to start phase II clinical trials of the other two candidate products in 2016. If AR101 can successfully pass the third phase of clinical trials, the company is confident that it will soon be approved by the FDA. The company has registered patents all over the world, and once approved, it will be able to quickly distribute the goods to all parts of the world.
Aimmune Therapeutics (AIMT) investment:
Aimmune submitted its IPO application on July 6, 2015, and plans to raise 115 million US dollars. It will be traded on NASDAQ under the stock code: AIMT.
Aimmune company official website: http://www.aimmune.com/
Aimmune American Stock Encyclopedia: https://www.thisyear.com/aimt.html